试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-05-10
A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors
编号:NCT02663518登记状态:提前终止企业 / 申办者:Pfizer
药物 / 成分:PF-0791800 (TTI-621)、PF-07901800 (TTI-621) plus Rituximab、PF-07901800 (TTI-621) plus Nivolumab
登记的停止原因(原文):Pfizer decided terminating study for administrative reasons on 22Mar2022 (stopping enrollment as of 15Apr2022). The decision wasn't due to safety concerns or requests from regulatory authorities.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-05-10
Effects of Cannabis on Cognition and Endocannabinoid Levels in Bipolar Disorder Patients and Healthy Volunteers
编号:NCT04231643登记状态:提前终止企业 / 申办者:University of California, San Diego
药物 / 成分:Dronabinol、Epidiolex、Placebos
登记的停止原因(原文):Budgetary limitations prevented us from completing our planned sample size.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-05-10
Study of a Nebulised Nitric Oxide Generating Solution in Patients With Mycobacterium Abscessus
编号:NCT05101915登记状态:提前终止企业 / 申办者:Papworth Hospital NHS Foundation Trust
药物 / 成分:RESP301
登记的停止原因(原文):TSC recommended early termination due to lack of futility of the trial.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-05-09
Adaptive Phase II Study to Evaluate the Safety & Efficacy of NaBen®
编号:NCT01908192登记状态:提前终止企业 / 申办者:SyneuRx International (Taiwan) Corp
药物 / 成分:NaBen®、Placebo
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-05-09
Triumeq As an Integrase Single Tablet Regimen in People With HIV Who Inject Drugs
编号:NCT02659761登记状态:提前终止企业 / 申办者:University College Dublin
药物 / 成分:dolutegravir/abacavir/lamivudine
登记的停止原因(原文):Sponsor decision due to slow recruitment rates and no future recruitment foreseen
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-05-09
MIcroglial Colony Stimulating Factor-1 Receptor (CSF1R) in Alzheimer's Disease
编号:NCT04121208登记状态:提前终止企业 / 申办者:University of Oxford
药物 / 成分:JNJ-40346527、Placebo
登记的停止原因(原文):Delayed due to COVID19. Study drug expired before could be used.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-05-08
Low-dose AZA, Pioglitazone, ATRA Versus Standard-dose AZA in Patients >=60 Years With Refractory AML
编号:NCT02942758登记状态:提前终止企业 / 申办者:University Hospital Regensburg
药物 / 成分:low-dose Azacitidine、Pioglitazone、ATRA、standard-dose AZA
登记的停止原因(原文):Due to financial reasons.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-05-08
Dopamine D2/D3 Receptor Upregulation by Varenicline in Methamphetamine Users
编号:NCT03059563登记状态:提前终止企业 / 申办者:University of California, Los Angeles
药物 / 成分:Varenicline、Placebo
登记的停止原因(原文):Global pandemic
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-05-08
Topical Antibiotic Irrigation (Gentamicin) in Prophylaxis of Midfacial Fracture Surgical Wounds
编号:NCT03483363登记状态:提前终止企业 / 申办者:The University of Texas Health Science Center, Houston
药物 / 成分:topical irrigation with gentamicin (80mg diluted in 1L 0.9% normal saline)、topical irrigation with sterile normal saline (NS)、intravenous (IV) prophylactic antibiotic
登记的停止原因(原文):recruitment issues
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-05-08
Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas
编号:NCT03670069登记状态:提前终止企业 / 申办者:Fred Hutchinson Cancer Center
药物 / 成分:Itacitinib、Laboratory Biomarker Analysis
登记的停止原因(原文):The study was terminated early with 27 out of 28 planned subjects enrolled. This decision was multifactorial, including slow enrollment in the last remaining cohort and a lack of evidence of clinical benefit.
查看官方原始记录 ↗